Personal tracking document — not medical advice, not a prescription. Learn more
Tracking protocol builder — GLP-1 · GIP · Glucagon
incretide builds your titration calendar, your nutrition targets and your decision points from the published data of the TRIUMPH[1] SURMOUNT[2] and STEP[3] programmes — then lays them out in an interactive tracking PDF. Nothing invented: every section cites its source.
SCHEDULES TAKEN FROM: NEW ENGLAND JOURNAL OF MEDICINE · 2021 · 2022 · 2023
One-off payment, no subscription — password-free account. Only your email is stored; your health data stays in your browser.
Retatrutide — Not approved in any country to date — schedule taken from a clinical trial protocol.
See the study →Tirzepatide — Approved (obesity) in several countries — SURMOUNT-1 trial schedule.
See the study →Semaglutide — Approved (obesity) in several countries — STEP-1 trial schedule.
See the study →Doses copied from forum to forum, numbers promised without a source, improvised titrations. Clinical trials, by contrast, publish precise, dated and verifiable schedules. incretide applies those schedules — no more, no less — and gives you a structured tracking document to discuss with a doctor.
Every dose, every step and every milestone comes from an identified publication.
NEJM, Diabetes Obesity and Metabolism, phase 3 results releases — cited section by section.
Never beyond the trial maximum. Any doubt at a decision point = 4 more weeks at the same dose.
Profile, goal, molecule, injection day: one question per screen, two minutes.
Dated titration, protein target, decision points, planned blood tests.
You confirm you understand this document is no substitute for medical follow-up.
6 pages with fillable fields: injections, decisions, check-ins, blood tests.
Weight, heart rate, tolerance: your PDF is regenerated pre-filled.
You pick the molecule; incretide applies the titration schedule of its reference trial, never going beyond the highest studied dose.
Triple GIP / GLP-1 / glucagon agonist
2 → 4 → 6 → 9 → 12 mg · 4-week steps
Highest studied dose: 12 mg/week
SourceJastreboff AM et al., NEJM 2023 (phase 2) · Giblin MJ et al., Diabetes Obesity and Metabolism 2026 (TRIUMPH design) · Eli Lilly, TRIUMPH-1 topline results, 21 May 2026
Not approved in any country to date — schedule taken from a clinical trial protocol.
Dual GIP / GLP-1 agonist
2.5 → +2.5 mg every 4 weeks → 15 mg max
Highest studied dose: 15 mg/week
SourceJastreboff AM et al., NEJM 2022 (SURMOUNT-1)
GLP-1 receptor agonist
0.25 mg → 4-week steps → 2.4 mg max
Highest studied dose: 2.4 mg/week
SourceWilding JPH et al., NEJM 2021 (STEP-1)
The full trial sheets: design, results, limits and regulatory status — Clinical studies page.
06The evidence room
Every incretide protocol applies the schedule of a published, registered clinical trial. We gave these three studies a full page — because trust should be verifiable.
2 → 4 → 6 → 9 → 12 mg · paliers de 4 semaines
−24,2 %
de poids corporel — moyenne de population, pas une promesse individuelle.
Jastreboff AM et al. — New England Journal of Medicine, 2023 PubMed
Non approuvée
2,5 mg → +2,5 mg toutes les 4 semaines → 15 mg max
−20,9 %
de poids corporel — moyenne de population, pas une promesse individuelle.
Jastreboff AM et al. — New England Journal of Medicine, 2022 PubMed
APPROUVÉE (OBÉSITÉ)
0,25 mg → paliers de 4 semaines → 2,4 mg max
−14,9 %
de poids corporel — moyenne de population, pas une promesse individuelle.
Wilding JPH et al. — New England Journal of Medicine, 2021 PubMed
APPROUVÉE (OBÉSITÉ)
Every step with its real dates, aligned with your injection day.
1.6 to 2.2 g/kg/day, translated into real portions.
At every step, 3 questions. A single “no” = 4 more weeks at the same dose.
ALT, AST, GGT, lipase, creatinine + eGFR, HbA1c, lipids, full blood count.
The symptoms that mean stopping and contacting a doctor, no hedging.
Click-to-fill fields: injections, decisions, check-ins, blood tests.
Premium access
The questionnaire is free. Full access — protocol, tracking, measurements, PDF — unlocks once and for good.
€99.00
one time — no subscription
VIP status guaranteed for life
Today the offer is a single payment. It may become a subscription for later joiners: by paying now, your access stays yours at no extra cost, even if prices change.
You only pay once your protocol has been generated and displayed.
ELSEWHERE: MONTHLY SUBSCRIPTION
Nothing to cancel here: your space, your check-ins and your PDF stay available, and you can request deletion of your data at any time.
Population averages observed in the reference trials. Orders of magnitude — never individual predictions.
of mean body weight at 48 weeks (12 mg) — phase 2
[1] Jastreboff AM et al. — Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023 · NCT04881760 PubMed
These averages come from participants followed in controlled trials, with support. Your own trajectory depends on many factors — which is why incretide shows ranges and plans decision points.
The full design of each study is on the Clinical studies page.
Your protocol shows an estimated trajectory as a band — derived from the published curves of the trial matching your molecule.
Trajectory — illustrative example (TRIUMPH schedule)
Fourchette d’ordre de grandeur dérivée des courbes publiées de l’essai de référence. Ceci n’est ni une prédiction, ni une promesse de résultat individuel. Exemple d’illustration : 90 kg vers 70 kg sur 48 semaines.
No. To date, retatrutide is not approved in any country. Its titration schedule comes from a published clinical trial protocol — it is presented as such, with its regulatory status shown everywhere. See the methodology
Two minutes of questions. A complete, sourced tracking document and an interactive PDF to share with your doctor.
One-time payment, no subscription · Password-free account · Only your email is stored — your health data stays in your browser
Delete your account in one click from My space.
